OrganoidScience Secures European Patent for Next-Generation Intestinal Tissue Regeneration Therapy

Technological Prowess Recognized in Europe Following the United States and Japan
New Treatment Approach Anticipated for Crohn's Disease and Ulcerative Colitis

OrganoidScience announced on the 3rd that the core technology for intestinal organoid regenerative therapy has received a decision for patent registration from the European Patent Office (EPO).

With this decision, the technology has now been officially recognized for its technological advancement and originality in Europe, following Korea, the United States, and Japan, thereby securing results in major global patent jurisdictions.

The newly registered patent covers a treatment strategy that applies intestinal organoids in combination with existing biological agents (TNF-α inhibitors) that suppress inflammation. It adds the concept of "regeneration" that actually restores damaged intestinal tissue to drug therapies that alleviate inflammation. Whereas existing treatments have focused on controlling inflammation, this technology focuses on restoring the intestinal mucosa, which has been disrupted by inflammation, back to a healthy state.

In particular, it is expected to demonstrate intestinal tissue regeneration effects in refractory patient groups whose symptoms have been controlled with drug therapy and have reached remission, but who still face a high risk of relapse because deep ulcers or damage in the intestinal mucosa have not healed. According to the company, this represents a new treatment approach that overcomes the long-standing limitation seen in many patients with Crohn's disease and ulcerative colitis, where "symptoms are controlled, but the intestine does not heal."

The technology can also be extended to a variety of intestinal diseases such as radiation colitis and ischemic colitis, and it encompasses a broad concept of intestinal organoids that is not limited to specific manufacturing processes or cell origins, which is expected to give it very high practical value. As it has been confirmed that administering organoid therapeutics in combination with existing biological agents maximizes therapeutic effects, its value is drawing attention as a "fundamental patent" with a high likelihood of being prescribed in combination in real-world clinical settings.

The company is also gaining momentum in its entry into the European market. OrganoidScience was selected in 2023 as a recipient of public funding in Germany and can receive support from the German government for up to 80% of the costs required for local clinical trials in Europe. Currently, OrganoidScience is accelerating clinical development in Europe and global partnerships using its German subsidiary, Lambda Biologics, as a base, and the company expects that this European patent registration will serve as a key turning point that accelerates commercialization and collaboration discussions aimed at the global market.

A company representative said, "This achievement is the result of major countries around the world officially recognizing that an intestinal organoid-based regenerative treatment strategy is a next-generation solution that can complement the limitations of existing therapies," adding, "We will focus on providing more fundamental and sustainable treatment options for patients with intestinal diseases."

This patent is protected in 18 major European countries, including Germany and France, under the Unitary Patent system, and the patent term will last until 2042. Upon obtaining marketing authorization for the pharmaceutical product, the rights can be extended until up to 2047.

This content was produced with the assistance of AI translation services.